IDO1 is a heme-enzyme that is induced by INF-γ and catalyzes the conversion of tryptophan to kynurenine. This leads to a depletion of tryptophan that results in T cells and dendritic cells inactivation. IDO activity has been identified as an important immune effector pathway in tumor cells to escape a potentially effective immune response. Inhibition of IDO1 has been found to delay cancer growth and enhance dendritic vaccines. Therapeutic inhibition of IDO1 is of interest because of its proposed role in the pathogenesis of several diseases, including cancer, hypotension, neurodegenerative disorders, and its potential to aid cancer immunotherapy and organ transplant.
This recombinant human IDO1 has a 6x histidine tag at its N-terminus. This product is lyophilized from a solution containing 10 mM Trizma buffer (pH 7.0), with 500 mM NaCl and a carbohydrate carrier.
Unit Definition
One unit of enzyme hydrolyzes 1.0 pmole of L-Tryptophan to N-formyl-Lkynurenine per minute at pH-6.5 at 37°C
European journal of nutrition, 59(8), 3591-3601 (2020-02-15)
Growing evidence shows that nutrient metabolism affects inflammatory bowel diseases (IBD) development. Previously, we showed that deficiency of indoleamine 2,3-dioxygenase 1 (Ido1), a tryptophan-catabolizing enzyme, reduced the severity of dextran sulfate sodium (DSS)-induced colitis in mice. However, the roles played
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.